Amiodarone
- Generic Name
- Amiodarone
- Brand Names
- Nexterone, Pacerone
- Drug Type
- Small Molecule
- Chemical Formula
- C25H29I2NO3
- CAS Number
- 1951-25-3
- Unique Ingredient Identifier
- N3RQ532IUT
- Background
Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation. Because of its ability to cause serious toxicity and possibly death, amiodarone use s...
- Indication
The FDA approved indications for amiodarone are recurrent ventricular fibrillation (VF) and recurrent hemodynamically unstable ventricular tachycardia (VT). The FDA emphasizes that this drug should only be given in these conditions when they are clinically documented and have not responded to normal therapeutic doses of other antiarrhythmic agents, or when o...
- Associated Conditions
- Atrial Fibrillation, Supraventricular Tachycardia (SVT), Recurrent Ventricular fibrillation, Recurrent hemodynamically unstable Ventricular tachycardia
- Associated Therapies
- -
Effectiveness of Repeated Amiodarone Dosing Regimen Versus Standard Dosing Regimen in Atrial Fibrillation Patient With Rapid Ventricular Response
- First Posted Date
- 2024-02-16
- Last Posted Date
- 2024-04-08
- Lead Sponsor
- Police General Hospital, Thailand
- Target Recruit Count
- 32
- Registration Number
- NCT06262932
Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-10-04
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 90
- Registration Number
- NCT06067438
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Pragmatic Amiodarone Trial to Reduce Postoperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery
- First Posted Date
- 2022-09-16
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 242
- Registration Number
- NCT05543278
MAGNAM Trial, Magnesium Versus Amiodarone in Atrial Fibrillation in Critical Care
- Conditions
- Interventions
- First Posted Date
- 2022-03-18
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Sunnybrook Health Sciences Centre
- Target Recruit Count
- 200
- Registration Number
- NCT05287191
- Locations
- 🇨🇦
Mount Sinai Hospital, Toronto, Ontario, Canada
🇨🇦University Health Network - Toronto General Hospital, Toronto, Ontario, Canada
🇨🇦Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Nifekalant Versus Amiodarone in New-Onset Atrial Fibrillation After Cardiac Surgery
- Conditions
- Interventions
- First Posted Date
- 2021-12-27
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Beijing Anzhen Hospital
- Target Recruit Count
- 274
- Registration Number
- NCT05169866
- Locations
- 🇨🇳
Beijing Anzhen Hospital, Beijing, China
Repeated Amiodarone Dosing In Cardiac surgicaL Procedures
- First Posted Date
- 2021-08-13
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Kevin W Hatton, MD, PhD
- Target Recruit Count
- 3
- Registration Number
- NCT05004077
- Locations
- 🇺🇸
University of Kentucky Medical Center, Lexington, Kentucky, United States
Shortening Duration of Antiarrhythmic Medication for SVT in Infants
- Conditions
- First Posted Date
- 2021-04-08
- Last Posted Date
- 2021-09-29
- Lead Sponsor
- Tampere University Hospital
- Target Recruit Count
- 70
- Registration Number
- NCT04837261
- Locations
- 🇫🇮
Hämeenlinna Central Hospital, Hämeenlinna, Kanta-Häme, Finland
🇫🇮Sakunta Central Hospital, Pori, Satakunta, Finland
🇫🇮Central Finland Central Hospital, Jyväskylä, Central Finland, Finland
Vernakalant Versus Amiodarone for Post-operative Atrial Fibrillation in Cardiac Surgery Patients
- Conditions
- Interventions
- First Posted Date
- 2021-02-10
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- University of Calgary
- Target Recruit Count
- 50
- Registration Number
- NCT04748991
Oral Amiodarone for Acute Cardioversion of Atrial Fibrillation Study
- Conditions
- Interventions
- First Posted Date
- 2020-10-20
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- University of Calgary
- Target Recruit Count
- 42
- Registration Number
- NCT04594746
- Locations
- 🇨🇦
University of Calgary, Calgary, Alberta, Canada
Prophylaxis for Patients at Risk to Eliminate Post-operative Atrial Fibrillation
- First Posted Date
- 2020-05-19
- Last Posted Date
- 2023-03-29
- Lead Sponsor
- Ottawa Hospital Research Institute
- Target Recruit Count
- 80
- Registration Number
- NCT04392921
- Locations
- 🇨🇦
The Ottawa Hospital, Ottawa, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.